# 바이오스페이스 일일 뉴스 리포트 - 2025년 10월 22일


## 주요 헤드라인

1. **Novo Foundation Replaces Pharma’s Board, Revealing Deep Divisions Over Leadership (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/novo-foundation-replaces-pharmas-board-revealing-deep-divisions-over-leadership>

2. **Novo Foundation Replaces Pharma’s Board, Revealing Deep Divisions Over Leadership (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/novo-foundation-replaces-pharmas-board-revealing-deep-divisions-over-leadership>

3. **Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/neuphorias-social-anxiety-drug-flunks-late-stage-trial>

4. **Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/neuphorias-social-anxiety-drug-flunks-late-stage-trial>

5. **Galapagos Exits Cell Therapy, Cuts 365 Employees (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/galapagos-exits-cell-therapy-cuts-365-employees>

6. **Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/exelixis-kinase-blocker-sets-new-survival-bar-in-third-line-colorectal-cancer-opening-road-to-fda>

7. **Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/summit-eyes-2025-fda-application-for-ivonescimab-despite-overall-survival-miss>


---
*2025년 10월 22일 바이오스페이스 뉴스 피드에서 생성된 리포트*